University of Exeter
Browse

Dupilumab reduced severe exacerbation rates and improved pre-bronchodilator Fev 1 in patients with moderate-to-severe asthma regardless of exacerbation history of 蠅1, 蠅2, or 蠅3 prior exacerbations: Liberty Asthma Traverse

Download (85.15 kB)
conference contribution
posted on 2025-08-01, 17:06 authored by JF Maspero, J Corren, C Katelaris, M Castro, MJC Humbert, DMG Halpin, A Altincatal, N Pandit-Abid, X Soler, A Radwan, JA Jacob-Nara, YM Deniz, PJ Rowe
No description available

Funding

Sanofi and Regeneron Pharmaceuticals, Inc.

History

Related Materials

  1. 1.
    EISSN - Is published in https://portal.issn.org/resource/ISSN/1535-4970
  2. 2.
    ISSN - Is published in https://portal.issn.org/resource/ISSN/1073-449X

Rights

© 2023 American Thoracic Society, All Rights Reserved.

Notes

This is the author accepted manuscript. The final version is available from the American Thoracic Society via the DOI in this record

External DOI

Journal

American Journal of Respiratory and Critical Care Medicine

Pagination

a4742-a4742

Publisher

American Thoracic Society

Name of conference

C31. BIOLOGICS WANT TO RULE THE (ASTHMA) WORLD

Version

  • Accepted Manuscript

Language

en

FCD date

2023-06-22T13:34:45Z

FOA date

2024-05-22T23:00:00Z

Citation

Vol. 207, article A4742

Department

  • Clinical and Biomedical Sciences

Usage metrics

    University of Exeter

    Categories

    No categories selected

    Keywords

    Respiratory

    Licence

    All rights reserved

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC